3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Prostatic Neoplasms
25
Lymphoma, Large B-Cell, Diffuse
24
Burkitt Lymphoma
19
Lymphoma, Follicular
14
Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasms
8
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
6
Recurrence
5
Prostatic Neoplasms, Castration-Resistant
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Prostate Cancer Metastatic
2
Plasmablastic Lymphoma
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Enteropathy-Associated T-Cell Lymphoma
2
Interventions
Cyclophosphamide
3
acalabrutinib
2
Rituximab
2
pembrolizumab
1
obinutuzumab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Doxorubicin
1
CA-4948
1
Busulfan
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
Prednisone
×
90 days
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled